Amgen earnings analysis: questions answered and next catalysts
Amgen Inc (AMGN) reported Q3 2026 earnings with adjusted EPS of $6.45 (beating estimates by 11.98%) and revenue of $10.40B. The stock is up 3.74% near its 52-week high. Guidance was raised, and key products showed growth, though some biosimilars faced erosion. Analysts have mixed views on valuation and future catalysts.
How this was made
The 30-second read
Why it matters
Guidance raises and positive Phase 3 readouts are near-term supportive, but the article highlights binary risk around MariTide obesity and stretched valuation versus several bank targets.
Market read
Traders get a guidance update with concrete numbers and a calendar of near-term scientific catalysts that can drive sentiment before the next earnings print.
What to watch
MariTide obesity strategy is described as unproven until 2027, and consensus EPS revisions are slightly negative over 30 days, which can dominate price action even after a guidance raise.
Background
The piece frames Amgen’s Q3 as a continuation of multiple EPS beats and focuses on whether growth products can offset biosimilar erosion, plus what to watch next across Phase 3 catalysts.
Ticker impact
Amgen reported Q3 results with adjusted EPS $6.45 vs $5.76 and raised 2026 revenue guidance to $38.9B-$39.7B, midpoint +$500M.
Likely upward bias as the market re-prices raised 2026 guidance, tempered by caution around Q4 seasonality and slightly negative EPS revisions.
The article provides fresh, company-specific guidance increases and Q3 beat figures, plus explicit remaining risks (MariTide obesity unproven, valuation stretched, EPS revisions slightly negative).
Market effects
Biopharma investors may rotate within cardiometabolic and oncology GLP-1 and antibody-drug pipelines based on Amgen’s read-across and Phase 3 momentum.
Limited direct regional spillover; primarily impacts US large-cap biotech sentiment and earnings/guidance expectations.
Global read-across catalysts (AHA meeting) can influence cross-asset biotech risk appetite internationally.
Counterpoint
Despite the beat, the stock is near 52-week highs and above multiple targets, so incremental good news may already be priced while downside risk concentrates around Q4 seasonality and biosimilar erosion.
Key entities
- companyAmgen Inc
Reported Q3 results, raised 2026 revenue and adjusted EPS guidance, and highlighted multiple Phase 3 readouts and upcoming catalysts.
- pipeline_programMariTide
Cardiovascular outcomes trial enrollment completed; obesity readouts expected in 2027, described as unproven until then.
- pipeline_programPelacarsen (Novartis)
Labeled as an Lp(a) Phase 3 data readout at AHA, used as a cardiovascular read-across catalyst.
